LAVA THERAPEUTICS NV (LVTX) Stock News
NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD
LVTX Latest News, Press Relases and Analysis
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial...
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson...
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the second quarter of...
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
LAVA Reports Second Quarter 2024 Financial Results and Business Update
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab...
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the first quarter of ...
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the fourth quarter of...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LAVA Announces Annual Meeting of Shareholders
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0...
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for...
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
LAVA stock rises on clinical trial collaboration with Merck (NASDAQ:LVTX)
LAVA Therapeutics surges as it partners with Merck for a clinical trial collaboration and supply agreement, boosting prostate cancer drug prospects.
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the...
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2...
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused...
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead...